Physician profile
Jared Sninsky
NPI 1083065965
$2,824.15
in general payments reported to CMS, 2019-2025
13 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $98.99 · 2021: $114 · 2022: $255 · 2023: $498 · 2024: $944 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.05 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.12 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $407.02 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $263.31 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.44 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $142.85 | 2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $112.49 | 2025 | Tremfya |
| Celgene Corporation | $100.09 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $97.91 | 2025 | Rezdiffra |
| Medtronic, INC. | $43.65 | 2023-2024 | Nexpowder, Pillcam |
| Merck Sharp & Dohme LLC | $38.55 | 2023-2024 | Dificid |
| Ardelyx, INC. | $14.76 | 2024 | Ibsrela |
| Boston Scientific Corporation | $12.96 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Sninsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.